Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-05-29
2007-05-29
Wehbe, Anne M. (Department: 1633)
Chemistry: molecular biology and microbiology
Vector, per se
C435S235100, C424S093200
Reexamination Certificate
active
10181697
ABSTRACT:
The present invention provides a herpes virus with improved oncolytic properties which comprises a gene encoding an immunomodulatory cytokine and which lacks a functional ICP34.5 gene and a functional ICP47 encoding gene.
REFERENCES:
patent: 5328688 (1994-07-01), Roizman
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5824318 (1998-10-01), Mohr et al.
patent: 5876923 (1999-03-01), Leopardi et al.
patent: 6428968 (2002-08-01), Molnar-Kimber et al.
patent: 6641817 (2003-11-01), Coffin et al.
patent: 6713067 (2004-03-01), Coffin
patent: 2322130 (1998-08-01), None
patent: WO-92/13943 (1992-08-01), None
patent: WO-93/15749 (1993-08-01), None
patent: WO 93/19591 (1993-10-01), None
patent: WO-95/16779 (1995-06-01), None
patent: 96/16164 (1996-05-01), None
patent: WO-97/04804 (1997-02-01), None
patent: WO-97/20935 (1997-06-01), None
patent: WO-97/26904 (1997-07-01), None
patent: 98/04726 (1998-02-01), None
patent: WO 98/04726 (1998-02-01), None
patent: WO-98/37905 (1998-09-01), None
patent: 98/42855 (1998-10-01), None
patent: 98/51809 (1998-11-01), None
patent: WO-99/07394 (1999-02-01), None
patent: WO 99/38955 (1999-08-01), None
patent: 00/08191 (2000-02-01), None
patent: WO-00/08051 (2000-02-01), None
patent: WO-00/40734 (2000-07-01), None
patent: WO 01 09361 (2001-02-01), None
patent: WO 01/46449 (2001-06-01), None
patent: WO 01/46450 (2001-06-01), None
patent: WO 01/53506 (2001-07-01), None
patent: WO 01/53507 (2001-07-01), None
Rekabdar et al. (1999) Clin. Diag. Lab. Immunol., vol. 6 (6) 826-831.
Andreansky et al. (1998) Gene Ther., vol. 5 (1), 121-130.
Shi et al. (1999) Canc. Gene. Ther.,vol. 6(1) 81-88.
Bronte et al. (1995) J. Immunol., vol. 154, 5282-5292.
Irvine et al. (1996) J. Immunol., vol. 156, 238-245.
Ace et al. “Construction and characterisation of a herpes simplex virus type 1 mutant unable to trasinduce immediate early gene expression” J. Virol. 63:2260-2269 (1989).
Chambers et al “Composition of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma” Proc. Natl. Acad. Sci. USA 92:1411-1415 (1995).
Chou et al. “Mapping of herpes simplex virus-1 neurovirulence to γ34.5, a gene nonessential for growth in culture” Science 250:1262-1266 (1990).
DeLuca et al. “Isolation and characterisation of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4” J. Virol. 56:558-570 (1985).
Gossen et al. “Transcriptional activation by tetracyclines in mammalian cells” Science 268:1766-1769 (1995).
Gossen & Bujard “Tight control of gene expression in mammalian cells by tetracyline-responsive promoters” Proc. Nat. Acad. Sci. USA 89:5547-5551 (1992).
Hill et al. “Herpes simplex virus turns off the TAP to evade host immunity” Nature 375:411-415 (1995).
Howard et al. “High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5” Gene Therapy 5:1137-1147 (1998).
Hunter et al. “Attenuated replication-competent herpes simplex virus type 1 mutant G207: Safety evaluation of intracerebral injection in non-human primates” J. Virol. 73:6319-6326 (1999).
Krisky et al. “Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons” Gene Therapy 5:1593-1603 (1998).
Maclean et al. “Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+between immediate early gene 1 and the “a” sequence” J. Gen. Virol. 72:631-639 (1991).
MacFarlane et al. “Hexamethylene bisacetamide stimulates herpes simplex virus immediate early gene expressions in the absence of trans-induction by Vmw65” J. Gen. Virology 73: 285-292 (1992).
Meignier et al. “In vivo behaviour of genetically engineered herpes simplex viruses R7017 and R7020: Construction and evaluation in rodents” J. Infect. Dis. 159:602-614 (1988).
Rice & Knipe “Genetic evidence for two distinct transactivation functions of the herpes simplex virus and protein ICP27” J. Virol. 64:1704-1715 (1990).
Samaniego et al. “Functional interactions between herpes simplex virus immediate-early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4” J. Virol. 69:5705-5715 (1995).
Samaniego et al. “Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins” J. Virol. 72:3307-3320 (1998).
Shi et al. “Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF” Cancer Gene Therapy 6:81-88 (1999).
Smiley & Duncan “Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 produces a phenotype similar to that of thein1814 linker insertion mutation” J. Virol. 71:6191-6193 (1997).
Smith et al. “Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression” Virol. 186:74-86 (1992).
Thomas et al. “Herpes simplex virus latency associated transcript encodes a protein which greatly enhances virus growth, can compensate for deficiencies in immediate-early gene expression, and is likely to function during reactivation from virus latency” J. Virol. 73:6618-6625 (1999).
Thompson et al. “DNA sequence and RNA transcription through a site of recombination in a non-neurovirulent herpes simplex virus intertypic recombinant” Virus Genes 1:275-286 (1988).
Coukos et al; “Use of Carrier Cells to Deliver a Replication-selective Herpes Simplex Virus-1 Mutant for the Intraperitoneal Therapy of Epithelial Ovarian Cancer” Clinical Cancer Research vol. 5: 1523-1537 (1999).
Andreansky et al, “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,” Proc. Natl. Acad. Sci. vol. 93, pp. 11313-11318 (Oct. 1996).
Chou et al, “The y134.5 Gene of Herpes Simplex Virus 1 Precludes Neuroblastoma Cells from Triggering Total Shutoff of Protein Synthesis Characteristic of Programmed cell Death in Neuronal Cells,” Proc. Natl. Acad. Sci. vol. 89, pp. 3266-3270 (Apr. 1992).
Chou et al, “Differential response of Human Cells to Deletions and Stop Codons in the Y134.5 Gene of Herpes Simplex virus,” Journal of Virology, pp. 8304-8311 (Dec. 1994).
Coukos et al, “Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53-independent Death and Is Efficacious against Chemotherapy-resistant Ovarian Cancer,” Clinical Cancer Research vol. 6, pp. 3342-3353 (Aug. 2000).
Ezzeddine et al, “Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Thymidine Kinase Gene,” The New Biologist vol. 3, No. 6, pp. 608-614 (Jun. 1991).
Markert, James et al, “Reduction and Elimination of Encephalitis in an Experimental Glioma Therapy Model with attenuated Herpes Simplex Mutants that Retain Susceptibility to Acyclovir,” Neurosurgery vol. 32 No. 4, pp. 597-603 (Apr. 1993).
Martuza et al, “Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant,” Science vol. 252, pp. 854-856.
McKie et al, “Selective in Vitro Replication of Herpes Simplex Virus Type 1 (HSV-1) ICP34.5 Null Mutants in Primary Human CNS Tumours—Evaluation of a Potentially Effective Clinical Therapy,” British Journal of Cancer vol. 74, pp. 745-752 (1996).
U.S. Appl. No. 10/181,692.
Krisky, D.M., et al.; Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications; Gene Therapy 5:151
Biovex Limited
Fulbright & Jaworski LLP
Wehbe Anne M.
LandOfFree
Herpes virus strains for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes virus strains for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes virus strains for gene therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793079